Our Mission
Jed Taxel died of rare cancer in 2017, six months after his initial diagnosis. The Jedi Rare Cancer Foundation is his legacy. Our mission and sole commitment is to accelerate scientific discovery that will change lives and enable better outcomes for rare cancer patients and their families.
We are investing in science and building a community of systemic support for concerted, collaborative innovation that will accelerate breakthroughs in rare cancer research, catalyze innovation among collaborators, and bring promising therapeutics to patients to defeat rare cancer. This is something we can and must do.
We Accelerate Discovery
Defeating rare cancer requires collaboration and coordination to build a movement that is committed to instituting a systemic community-wide approach to defeat rare cancer as we know it. Together with our medical science and patient advocacy partners, we strive to advance the understanding and treatment of rare forms of cancer.
Our Priorities
We support scientific research, advocacy, and community engagement to make a lasting impact in the field of rare cancer research. We strive to raise awareness, support cutting-edge research initiatives, and accelerate clinical trials of lifesaving treatments for rare cancer patients. By collaborating with other foundations and organizations, we aim to foster synergies and accelerate progress leading to improved outcomes for individuals and their families affected by a challenging rare cancer diagnosis.
Meet Mark Taxel, Chair and Founder
